Sigma ligands, but not N-methyl-d-aspartate antagonists, reduce levodopa-induced dyskinesias

Levodopa (l-DOPA) is the ‘gold standard’ to treat Parkinson's disease. Unfortunately, dyskinesias detract from its efficacy. Current dyskinesia treatments, including amantadine and dextromethorphan, are thought to work via N-methyl-d-aspartate (NMDA) antagonism, but this hypothesis has not been...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Paquette, Melanie A., Brudney, Elizabeth G., Putterman, Daniel B., Meshul, Charles K., Johnson, Steven W., Berger, Stephen Paul
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2845294/
https://ncbi.nlm.nih.gov/pubmed/18281903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/WNR.0b013e3282f3b0d1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares